JP2024546569A5 - - Google Patents

Info

Publication number
JP2024546569A5
JP2024546569A5 JP2024524692A JP2024524692A JP2024546569A5 JP 2024546569 A5 JP2024546569 A5 JP 2024546569A5 JP 2024524692 A JP2024524692 A JP 2024524692A JP 2024524692 A JP2024524692 A JP 2024524692A JP 2024546569 A5 JP2024546569 A5 JP 2024546569A5
Authority
JP
Japan
Application number
JP2024524692A
Other languages
Japanese (ja)
Other versions
JPWO2023114875A5 (https=
JP2024546569A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081596 external-priority patent/WO2023114875A1/en
Publication of JP2024546569A publication Critical patent/JP2024546569A/ja
Publication of JPWO2023114875A5 publication Critical patent/JPWO2023114875A5/ja
Publication of JP2024546569A5 publication Critical patent/JP2024546569A5/ja
Pending legal-status Critical Current

Links

JP2024524692A 2021-12-15 2022-12-14 がんに対するwee1阻害剤 Pending JP2024546569A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163265438P 2021-12-15 2021-12-15
US63/265,438 2021-12-15
PCT/US2022/081596 WO2023114875A1 (en) 2021-12-15 2022-12-14 Wee1 inhibitor for cancer

Publications (3)

Publication Number Publication Date
JP2024546569A JP2024546569A (ja) 2024-12-26
JPWO2023114875A5 JPWO2023114875A5 (https=) 2025-12-23
JP2024546569A5 true JP2024546569A5 (https=) 2025-12-23

Family

ID=86773533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524692A Pending JP2024546569A (ja) 2021-12-15 2022-12-14 がんに対するwee1阻害剤

Country Status (9)

Country Link
US (1) US20240335447A1 (https=)
EP (1) EP4447974A4 (https=)
JP (1) JP2024546569A (https=)
KR (1) KR20240119059A (https=)
CN (1) CN118201616A (https=)
AU (1) AU2022414090A1 (https=)
CA (1) CA3235595A1 (https=)
MX (1) MX2024004157A (https=)
WO (1) WO2023114875A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
BR112023000350A2 (pt) 2020-07-09 2023-03-28 Recurium Ip Holdings Llc Sais e formas de um inibidor de wee1
WO2025184572A1 (en) * 2024-03-01 2025-09-04 Zeno Management, Inc. Wee1 inhibitor combination therapy
WO2025261307A1 (zh) * 2024-06-17 2025-12-26 首药控股(北京)股份有限公司 治疗肿瘤的药物组合及用途
CN121159528A (zh) * 2025-07-25 2025-12-19 天津医科大学总医院 一种PROTAC化合物及其制备方法和作为靶向PTRF/Cavin1的降解剂的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017003502A1 (en) * 2015-07-01 2017-01-05 Dignity Health Systems and methods for treating cancer
MX2020009372A (es) * 2018-03-09 2020-10-14 Recurium Ip Holdings Llc 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13176U (https=)